Global Erythropoietin Stimulating Agents Market to grow with a CAGR of 8.14%
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Erythropoietin Stimulating Agents Market.
According to TechSci
Research report, “Global Erythropoietin Stimulating Agents Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”,
Global Erythropoietin Stimulating Agents Market has valued at USD 16.20 billion
in 2022 and is anticipated to witness an impressive growth in the forecast
period with a CAGR of 8.14% and will probably reach 7.45 billion by 2028. This can be due to collaborations and partnerships among
leading companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market.
Patient awareness and
advocacy can play a significant role in driving the global Erythropoietin
Stimulating Agents (ESAs) market. Erythropoietin Stimulating Agents are
pharmaceutical drugs used to treat anemia, particularly in patients with
chronic kidney disease, cancer, or undergoing certain medical treatments like
chemotherapy. When patients and their caregivers are well-informed about ESA
treatments and their benefits, there is likely to be an increased demand for
these drugs. Patients who understand how ESAs can improve their quality of life
may be more inclined to request these medications from their healthcare
providers. Patient advocacy groups often work to raise awareness about specific
medical conditions and advocate for increased research funding. In the case of
anemia related to chronic illnesses, such as chronic kidney disease, these
groups can push for more research into ESA therapies, leading to the
development of new and improved drugs. Patient advocacy groups often provide
educational resources to patients and healthcare professionals. These resources
can help healthcare providers better understand when ESA treatments are
appropriate and how to use them effectively, potentially leading to increased
ESA prescriptions.
Browse over XX market
data Figures and spread through 110 Pages and an in-depth TOC on " Global Erythropoietin Stimulating Agents Market.”
Erythropoietin
Stimulating Agents (ESAs) are a class of pharmaceutical drugs designed to
stimulate the production of red blood cells (erythropoiesis) in the bone
marrow. These agents are primarily used in the treatment of anemia, which is a
condition characterized by a reduced number of red blood cells or a decreased
ability of red blood cells to carry oxygen. Anemia can occur due to various
underlying medical conditions, such as chronic kidney disease, cancer, certain
types of anemia (like chemotherapy-induced anemia), and other chronic
illnesses.
In July 2020, A phase
III trial is being conducted to see if efepoetin alfa delivered subcutaneously
is as efficient and well tolerated as subcutaneous Mircera for the treatment
and maintenance of anaemia in CKD patients not receiving dialysis. An 8-week
evaluation phase will be used to gauge the effectiveness of the corrective
treatment after a 20-week correction period for dosage titration and Hb
correction. To determine long-term safety and maintenance effect, subjects who
respond to efepoetin alfa (defined as an increase in Hb 1.0 g/dL versus
baseline and Hb level within 10 - 12 g/dL range without blood transfusion
during the 28 weeks after the first dose) will be randomly assigned to receive
subcutaneous efepoetin alfa once every 2W or once every 4W for an additional
24-week extension period.
Healthcare cost
containment has been a significant challenge for the Global Erythropoietin
Stimulating Agents (ESA) Market. The cost of ESA therapies can be high,
particularly for the original branded products. Healthcare systems and payers
often seek to negotiate lower prices or reimbursement rates for these
medications to contain costs. he introduction of biosimilar versions of ESAs
has increased competition in the market. Biosimilars are typically priced lower
than the original branded products, leading to price erosion and cost
containment. Payers, including government healthcare programs and private
insurance companies, may implement reimbursement policies that restrict ESA use
to specific patient populations or clinical indications. These policies aim to
control costs by ensuring that ESAs are used judiciously. Healthcare providers
often follow clinical guidelines that recommend ESA use based on specific
criteria, such as hemoglobin levels. These guidelines may limit ESA
administration to patients who meet certain criteria, reducing unnecessary
utilization.
Global Erythropoietin
Stimulating Agents Market segmentation is based on Type, Application, and
Region.
Based on Application,
Global Erythropoietin Stimulating Agents Market is segmented into Cancer, Renal
Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications.
Erythropoietin Stimulating Agents (ESAs) are commonly used in the management of
renal disorders, particularly in conditions associated with anemia caused by
impaired red blood cell production. The primary renal disorder where ESAs are
frequently employed is chronic kidney disease (CKD), but they may also be used
in other kidney-related conditions. CKD often leads to anemia due to the
kidneys' reduced ability to produce erythropoietin, a hormone that stimulates
red blood cell production in the bone marrow. ESAs, such as Epoetin Alfa and
Darbepoetin Alfa, are prescribed to raise hemoglobin levels and treat anemia in
CKD patients.
Based on Region, North
America dominated the Global Erythropoietin Stimulating Agents Market. North
America is a hub for clinical research and innovation in healthcare. This
includes research into ESA therapies, which can lead to the development of new
products and treatment approaches. Clinical trials are often conducted in the
region. Regulatory agencies such as the U.S. Food and Drug Administration (FDA)
play a crucial role in approving and regulating ESA products. A favorable
regulatory environment can contribute to ESA accessibility in North America.
Many individuals in North America have health insurance coverage, which can
make ESA therapies more accessible and affordable. Health insurance policies
often cover treatments for chronic conditions like anemia associated with CKD
or cancer.
Asia-pacific region to
fastest growth in the Global Erythropoietin Stimulating Agents Market. The APAC
region is home to a significant and rapidly aging population. As people age,
the prevalence of anemia-related conditions, such as chronic kidney disease
(CKD) and cancer, tends to increase. This growing aging population drives the
demand for ESA therapies to manage anemia associated with these conditions.
Many countries in the APAC region have been increasing their healthcare
expenditure to improve healthcare infrastructure and access. This includes
investments in the treatment of chronic diseases and supportive therapies like
ESA treatments. The region has seen a rising incidence of chronic diseases,
including CKD and cancer, which often lead to anemia. This trend increases the
pool of potential ESA users in the region.
Some of the major
companies operating in the Global Erythropoietin Stimulating Agents Market
include:
- Amgen Inc.
- Biocon Limited
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd
- Intas Pharmaceuticals
Ltd
- Johnson and Johnson
- Pfizer Inc.
- Teva Pharmaceutical
Industries Ltd
- Thermo Fisher Scientific
- LG Lifesciences, Ltd
- Novartis AG(Sandoz)
- Panacea Biotec Ltd
Download Free Sample Report
Customers can also
request 10% free customization on this report.
“Certain areas, particularly in North America,
are projected to exert significant demand for Erythropoietin Stimulating
Agents. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Erythropoietin Stimulating Agents Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.Erythropoietin Stimulating
Agents Market - Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented by Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And
Other Types), Application (Cancer, Renal Disorders, Anti-retroviral Treatment,
Neural Diseases, and Other Applications), and By Region, Competition evaluated
the future growth potential of Global Erythropoietin Stimulating Agents Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Erythropoietin Stimulating Agents
Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com